Trial Profile
Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 16 Apr 2024
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Carboplatin; Docetaxel; Pegfilgrastim
- Indications Advanced breast cancer; Early breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- Acronyms NeoPACT
- 06 Jun 2023 Results(n=110) assessing the impact of proliferation gene expression on efficacy of NAST in sTIL-high and sTIL-low TNBC presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 07 Jun 2022 Clinical and biomarker results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 06 Jun 2022 Planned primary completion date changed from 15 May 2022 to 15 May 2023.